buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 500-count bottle, Rx Only, Manufactured...
FDA Drug Recall #D-1513-2014 — Class III — July 14, 2014
Recall Summary
| Recall Number | D-1513-2014 |
| Classification | Class III — Low risk |
| Date Initiated | July 14, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Wockhardt Usa Inc. |
| Location | Parsippany, NJ |
| Product Type | Drugs |
| Quantity | 840 bottles |
Product Description
buPROPion HCl Extended-Release Tablets, USP (SR), 100 mg, 500-count bottle, Rx Only, Manufactured by: Wockhardt Limited, Mumbai, India; Distributed by: Wockhardt USA, LLC, 20 Waterview Blvd, Parsippany, NJ 07054 USA, NDC 64679-101-07.
Reason for Recall
Failed Impurities/Degradation Products: Out of specification levels of the impurity m-chlorobenzoic acid were observed.
Distribution Pattern
Nationwide
Lot / Code Information
Lot #: DN10635, Exp 01/15; DM13402, DN10247, Exp 11/14; and DM13449, Exp 07/14
Other Recalls from Wockhardt Usa Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0051-2018 | Class III | Enalapril Maleate tablets, USP, 5mg, 1000-count... | Aug 22, 2017 |
| D-1347-2015 | Class II | Lisinopril Tablets USP, 20 mg, 1000-count bottl... | Jul 29, 2015 |
| D-1346-2015 | Class II | Lisinopril Tablets USP, 5 mg, 1000-count bottle... | Jul 29, 2015 |
| D-1266-2015 | Class II | Famotodine Tablets, USP, 20 mg Tablets, For Rep... | Apr 22, 2015 |
| D-1271-2015 | Class II | Metoprolol Succinate Extended-Release Tablets, ... | Apr 22, 2015 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.